Vivagel BV Projections

I have had some thoughts on the Vivagel BV business which are contained in the PDF. The three parts of the projection are for the U.S., Europe and Other. The populations are for women between the 15 and 64 and are accurate for Europe and U.S. I just assumed a similar population number to Europe for other markets which would include Oceania, China, Japan, South America, etc.

Rates of BV are from Starpharma projections.

Take up in 2018 is low but it grows quickly because BV is a condition which women will want to treat, because it effects their ability to have children.

I have assumed licence income is pretty much all profit, there will be expenses but these will not be great.

The PE ration is also an assumption to achieve a share price.

Note that this projections is only Vivagel BV and NOTHING else.

Enjoy....

https://hotcopper.com.au/attachments/vivagel-pdf.695637/